SCHEMBL4913672

SCHEMBL4913672

Cc1ccc(CNCCNCCNCCNCc2ccc(C)cc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 5/20 0.79
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
TDP1 Q9NUW8 1/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
HDAC3 O15379 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
HDAC9 Q9UKV0 2/20 0.47
HDAC5 Q9UQL6 2/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4917450 1.00 CHRM2 (0.79) CHRM2MEN1KMT2ATDP1CA12
SCHEMBL5032223 1.00 CHRM2 (0.79) CHRM2MEN1KMT2ATDP1CA12
SCHEMBL4919923 0.97 CHRM2 (0.75) CHRM2MEN1KMT2ATDP1CA12
SCHEMBL4917375 0.89 CHRM2 (0.71) CHRM2MEN1KMT2ATDP1CA12
SCHEMBL4918917 0.89 CHRM2 (0.71) CHRM2MEN1KMT2ATDP1CA12
SCHEMBL4909529 0.89 CHRM2 (0.71) CHRM2MEN1KMT2ATDP1CA12
SCHEMBL14045032 0.89 CHRM2 (0.64) CHRM2MEN1KMT2ATDP1CA12
SCHEMBL9973111 0.89 MEN1 (0.74) CHRM2MEN1KMT2ATDP1NPC1
SCHEMBL842161 0.87 CHRM2 (0.67) CHRM2MEN1KMT2ATDP1CA12
SCHEMBL23709459 0.87 CHRM2 (0.62) CHRM2MEN1KMT2ATDP1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3390483-B1 ENCAPSULATION PROCTER & GAMBLE (US) 2022-05-18 EP disclosed
EP-3368207-B1 ENCAPSULATION ENCAPSYS LLC (US) 2021-12-01 EP disclosed
US-10864167-B2 Encapsulation THE PROCTER & GAMBLE COMPANY (US) 2020-12-15 US disclosed
EP-3390483-A1 ENCAPSULATION The Procter and Gamble Company (US) 2018-10-24 EP disclosed
EP-3368207-A1 ENCAPSULATION ENCAPSYS, LLC (US) 2018-09-05 EP disclosed
US-20180235893-A1 ENCAPSULATION THE PROCTER & GAMBLE COMPANY 2018-08-23 US disclosed
US-9937477-B2 Encapsulation WATERTITE PRODUCTS, INC. 2018-04-10 US disclosed
EP-1914254-B1 Crosslinkers for improving stability of polyurethane foams EVONIK DEGUSSA GMBH (DE) 2017-08-23 EP disclosed
WO-2017074997-A1 ENCAPSULATION ENCAPSYS, LLC (US) 2017-05-04 WO disclosed
WO-2017074995-A1 ENCAPSULATION ENCAPSYS, LLC (US) 2017-05-04 WO disclosed
US-20170113200-A1 Encapsulation Encapsys,LLC (US) 2017-04-27 US disclosed
US-8552078-B2 Non-fugitive tertiary amine catalyst and alkylated polyamine crosslinking additives; aging resistance AIR PRODUCTS AND CHEMICALS, INC. (US) 2013-10-08 US disclosed
EP-1914254-A1 Crosslinkers for improving stability of polyurethane foams Air Products and Chemicals, Inc. (US) 2008-04-23 EP disclosed
US-20080090922-A1 Crosslinkers for improving stability of polyurethane foams EVONIK OPERATIONS GMBH (DE) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180235893-A1 ENCAPSULATION ACR, ACMSD, SAMM50 CHRM2 1120/4885MEN1 2236/4885KMT2A 1601/4885
US-10864167-B2 Encapsulation ACR, MPHOSPH6, ACMSD CHRM2 993/4885MEN1 1901/4885KMT2A 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.